Analysts have clear opinions on HCAT.

Health Catalyst, Inc. (HCAT) is followed by analysts on the street.

John Ransom from Raymond James rates it a Buy with a target of $46.00.

Similarly, 3 months ago Sean Wieland of Piper Sandler Reiterated a Buy with a target of $49.00.

The consensus on the street is null.

What does Health Catalyst, Inc.(HCAT) do ?
Health Catalyst, Inc. provides healthcare data warehousing and process improvement solutions. Its solutions include accountable care, analytics adoption model, care management solutions, healthcare analytics, late-binding data warehouse, population health management, and predictive analytics. The company operates through two segments: Technology and Professional Services. Its Technology segment includes data platform, analytics applications and support services; and Professional Services segment is the combination of analytics, implementation, strategic advisory, and improvement services. Health Catalyst was founded by Steven C. Barlow and Thomas D. Burton in 2008 and is headquartered in Salt Lake City, UT.

Health Catalyst, Inc. (HCAT) Insider Trades